Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $27.40

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been given an average rating of "Moderate Buy" by the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $27.40.

A number of brokerages recently weighed in on OTLK. Guggenheim reaffirmed a "buy" rating and issued a $12.00 target price on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research lowered their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, November 29th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. Finally, Chardan Capital reissued a "neutral" rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd.

Outlook Therapeutics Stock Up 5.7 %

Shares of OTLK stock traded up $0.10 on Friday, reaching $1.84. The company's stock had a trading volume of 406,018 shares, compared to its average volume of 883,411. The company has a market capitalization of $58.84 million, a P/E ratio of -0.21 and a beta of 0.58. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The stock's 50 day simple moving average is $1.86 and its 200-day simple moving average is $4.56.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.06. Research analysts expect that Outlook Therapeutics will post -2.25 EPS for the current year.

Hedge Funds Weigh In On Outlook Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its stake in Outlook Therapeutics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock worth $32,000 after purchasing an additional 17,119 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Outlook Therapeutics in the 4th quarter valued at about $48,000. Christensen King & Associates Investment Services Inc. bought a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at about $55,000. Bank of New York Mellon Corp boosted its holdings in Outlook Therapeutics by 44.8% during the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock valued at $56,000 after acquiring an additional 9,211 shares during the period. Finally, AQR Capital Management LLC bought a new position in Outlook Therapeutics during the 2nd quarter worth approximately $75,000. Institutional investors own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.